Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): On Tuesday heightened volatility was witnessed in Regeneron Pharmaceuticals, Inc. The 12-month average price target assigned to the stock is $632.80, which implies an upside of 15.0% from current levels. (NASDAQ:REGN) is $605.93 and the 52-week low is $320.06. During the same quarter in the previous year, the company earned $2.47 earnings per share.
According toTipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Matt Roden and Gbola Amusa MD CFA have a total average return of 32.0% and 14.3% respectively. Company shares. In the past six months, there is a change of -28.44% in the total insider ownership. Chardan Capital lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $565.00 price target for the company.in a report on Monday, August 31st.
Regeneron Pharmaceuticals (NASDAQ:REGN) Director Charles A. Baker sold 5,000 shares of the stock in a transaction on Thursday, September 17th.
Shares of Regeneron Pharmaceuticals, Inc. Institutional Investors own 73.8% of Company shares. Previously, the analysts had a Sell rating on the shares. According to the latest available information, the firm will issue their earnings release on or around 2015-11-03. The company shares have rallied 52.91% in the past 52 Weeks.
On a technical level the stock has a 50 Day Moving Average of 545.317. REGN has a 1-year high of $605.93 and a 1-year low of $320.06. As of December 31, 2011, the Company had 13 product candidates in clinical development.
Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medications for eye diseases, colorectal cancer, and a rare inflammatory illness and has product candidates under development in other places, including hypercholesterolemia, oncology, rheumatoid arthritis (NASDAQ:REGN), asthma and atopic dermatitis.
Regeneron utilized its proprietary VelociGene® and VelocImmune® technologies, which enable the rapid identification and preclinical validation of fully human monoclonal antibodies, to develop a novel antibody therapy “cocktail” which includes a mixture of three antibodies. Regenerons discovery platforms are designed to identify specific proteins of therapeutic interest for a particular disease or cell type and validate these targets through high-throughput production of genetically modified mice using the Companys VelociGene technology to understand the role of these proteins in normal physiology, as well as in models of disease. The Business ‘s marketed products contain EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use.